Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : Reports Third Quarter 2016 Financial and Operating Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/17/2016 | 06:03pm CET

By a News Reporter-Staff News Editor at Clinical Trials Week -- Ophthotech Corporation (Nasdaq: OPHT) announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's business and product development programs (see also Ophthotech Corporation).

The Company expects to announce initial topline data from two Phase 3 trials of Fovista® (pegpleranib) in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD) in this fourth quarter. A third Phase 3 trial investigating Fovista® in combination with either Eylea® (aflibercept) or Avastin® (bevacizumab) completed patient recruitment in June 2016. The Company expects initial topline data from this third Phase 3 trial to be available in the second half of 2017.

Results from Ophthotech's Phase 2b Fovista® combination therapy study in wet AMD patients were published in October 2016 in Ophthalmology®, the journal of the American Academy of Ophthalmology. The published article, "Dual Antagonism of PDGF and VEGF in Neovascular Age-related Macular Degeneration," can be accessed online under "Articles in Press" at: http://www.aaojournal.org/inpress.

Ophthotech continues to enroll patients in its Phase 2/3 trial of Zimura® in patients with geographic atrophy, an advanced form of dry AMD. In addition, its Phase 2 trial evaluating the potential role of Zimura® when administered in combination with anti-VEGF drugs for the treatment of wet AMD has been activated.

Keywords for this news article include: Clinical Research, Retinal Degeneration, Investment and Finance, Ophthotech Corporation, Clinical Trials and Studies, Eye Diseases and Conditions, Retinal Diseases and Conditions, Age-Related Macular Degeneration.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPHTHOTECH CORP
11/17 OPHTHOTECH : Reports Third Quarter 2016 Financial and Operating Results
11/10 OPHTHOTECH : Announces the Publication of Fovista® in Combination with Lucentis®..
11/09 OPHTHOTECH : Reports Third Quarter 2016 Financial and Operating Results
11/08 OPHTHOTECH : Management's Discussion and Analysis of Financial Condition and Res..
11/08 OPHTHOTECH CORPORATION (NASDAQ : OPHT) Files An 8-K Reports Third Quarter 2016 F..
11/08 OPHTHOTECH CORP. : Results of Operations and Financial Condition, Financial Stat..
11/08 OPHTHOTECH : reports 3Q loss
11/08 OPHTHOTECH : Reports Third Quarter 2016 Financial and Operating Results
11/04 OPHTHOTECH CORP. : Entry into a Material Definitive Agreement (form 8-K)
10/31 OPHTHOTECH : Announces the Publication of Fovista® in Combination with Lucentis®..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/01 Significant Upside Potential For Ophthotech Before Phase 3 Fovista Readout
11/28 OPHTHOTECH : An Emerging Eye Disease Drug Company With A Near-Term Catalyst Due
11/28 Midday Gainers / Losers
11/08 Ophthotech's (OPHT) CEO Dr. David Guyer on Q3 2016 Results - Earnings Call Tr..
11/08 Ophthotech misses by $0.07, misses on revenue
Advertisement
Financials ($)
Sales 2016 60,8 M
EBIT 2016 -177 M
Net income 2016 -172 M
Finance 2016 13,6 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 22,1x
EV / Sales 2017 12,5x
Capitalization 1 360 M
More Financials
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Full-screen chart
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 90,2 $
Spread / Average Target 137%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David R. Guyer Chairman & Chief Executive Officer
Samir Chandrakant Patel President & Vice Chairman
Glenn P. Sblendorio Treasurer, Chief Financial & Operating Officer
Harvey N. Masonson Senior Vice President-Clinical Development
Axel Bolte Independent Class II Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-51.48%1 360
AMGEN, INC.-11.29%108 084
GILEAD SCIENCES, INC.-28.43%95 331
CELGENE CORPORATION-2.67%90 358
REGENERON PHARMACEUTIC..-31.88%39 005
ACTELION LTD45.20%21 671
More Results